The effect of topirxostat on hemodialysis patient with hyperuricemia

The effect of topirxostat on hemodialysis patient with hyperuricemia - Topiroxostat on hemodialysis patient

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026620

Enrollment

Registered

2017-03-21

Start date

2014-06-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperuricemia

Interventions

topiroxostat allopurinol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: hyperuricemia in hemodialysis

Exclusion criteria

Exclusion criteria: uric acid disorder

Design outcomes

Primary

Measure	Time frame
serum uric acid	—

Countries

Japan

Contacts

Public ContactYoshihiko KANOO

TMU Dept of Nephrology

kannoyh@tokyo-med.ac.jp0333426111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026